AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 141 min read$BLTE

Chuang Hao-Yuan sold $66K of BLTE

Chuang Hao-Yuan (Chief Financial Officer) sold 367 shares of BELITE BIO, INC (BLTE) at an average of $180.35 ($180.00–$180.57) across 2 trades on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chuang Hao-Yuan
Published Aug 14, 2026, 10:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 10:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Neutral
medium confidence
Mentioned
$BLTE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTENeutralLow
01

Why it matters

The newest disclosed fact is the CFO’s open-market sale of 367 shares on 2026-08-12, filed on 2026-08-14, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may treat this as routine insider liquidity rather than a strong fundamental catalyst.

03

What to watch

The sale size is small relative to typical company float, and the price range ($180.00 to $180.57) suggests execution around a specific window rather than a broad directional bet.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-14 after 2026-08-12 sale execution

Background

The article is a SEC Form 4 insider transaction disclosure for Belite Bio, Inc.

Company-level read

Ticker impact

$BLTENeutralMedium confidence
Context

Belite Bio CFO Chuang Hao-Yuan sold 367 shares in open-market transactions at about $180.35 per share under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is an insider transaction (not a buy), but it is explicitly under a Rule 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Sector

No clear sector read-through from a single CFO 10b5-1 sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with internal caution, so traders may still watch for follow-on disclosures.

Key entities

  • issuer
    BELITE BIO, INC

    Company whose CFO insider sale is disclosed on Form 4.

  • insider
    Chuang Hao-Yuan

    Chief Financial Officer and officer/director who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

SEP 4
$BLTEMedAI 8/10

Belite Bio (BLTE) Is Up 9.0% After FDA Grants Priority Review To Tinlarebant Stargardt NDA

Belite Bio (BLTE) shares rose 9.0% after the FDA granted priority review to its new drug application for tinlarebant, a treatment for Stargardt disease. The company expects a decision by February 12, 2027, and is preparing for commercial launch, targeting 53,000 patients. Phase III data showed a 35.7% reduction in lesion growth versus placebo. The company projects $563.2 million revenue and $318.3 million earnings by 2029, a 24% upside to its current price.

simplywall.st3 min
AUG 12
$BLTEMedAI 8/10

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio (BLTE) said the FDA accepted its tinlarebant NDA for Stargardt disease type I and granted priority review. A decision is expected Feb. 12, 2027. Priority review targets action in six months. The filing is based on Phase III DRAGON results showing a 35.7% reduction in atrophic lesion growth rate vs placebo. BLTE shares rose about 6.2% on Tuesday.

tradingview.com4 min
AUG 12
$BLTEMedAI 8/10

Belite Bio lands priority review for first Stargardt treatment

The FDA accepted and granted priority review to Belite Bio’s (Nasdaq: BLTE) New Drug Application for tinlarebant to treat Stargardt disease type 1. The Prescription Drug User Fee Act target action date is Feb. 12, 2027. The program previously received breakthrough therapy, fast track, and rare pediatric designations, and has orphan drug status in multiple regions.

thepharmaletter.com4 min
JUL 20
$BLTEMedAI 8/10

Why Is Belite Bio Stock Gaining Monday? - Belite Bio (NASDAQ:BLTE)

Belite Bio (NASDAQ:BLTE) reported additional secondary endpoint statistics from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1. The company said qAF stayed stable or fell about 2% at 25 months with tinlarebant versus about a 20% increase with placebo, and the trial previously met its primary endpoint, reducing retinal lesion growth by 35.7% versus placebo. BLTE shares rose about 3.11% to $154.74.

benzinga.com4 min